# A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC

> **NCT04167774** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 62 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** nb-Paclitaxel

## Key facts

- **NCT ID:** NCT04167774
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2019-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167774, "A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04167774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*